Last reviewed · How we verify
Utidelone in combination with capecitabine
At a glance
| Generic name | Utidelone in combination with capecitabine |
|---|---|
| Sponsor | Biostar Pharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases (PHASE2)
- Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE2, PHASE3)
- A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC (PHASE2)
- Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer (PHASE2)
- Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy (PHASE2)
- Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors (PHASE1)
- Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. (PHASE2)
- Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: